Apr 17, 2023
FDA Approves Omisirge, a Cell Therapy for Blood Cancer Patients Undergoing Stem Cell Transplantation
The FDA has recently approved a cell therapy called Omisirge (omidubicel-onlv) for patients with blood cancers who are undergoing stem cell transplantation. This allogeneic cord blood-based cell therapy can help speed up the recovery of neutrophils in the body, a type of white blood cell, and reduce the risk of infection. Omisirge is intended for use in adults and pediatric patients 12 years and…
View On WordPress
#allogeneic cord blood-based cell therapy#allogeneic stem cells#bacterial infections#blood cancers#breakthrough therapy#cell therapy#engraftment syndrome#FDA#fungal infections#graft failure#graft-versus-host disease#infection#infusion reactions#innovative therapies#myeloablative conditioning regimen#neutrophils#nicotinamide#Omisirge#randomized multicenter study#rare genetic diseases#secondary malignancies#side effects#stem cell transplantation#transmission of serious infections#umbilical cord blood#white blood cell